title: [Evolution of lower urinary tract symptoms under silodosin: factors influencing patients' satisfaction].
abstract: The objective of this study was to analyze the efficacy and safety of silodosin in patients with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) in current urologic practice.
  
  
  METHODS
  This was a prospective observational study conducted by 272 urologists on patients treated by silodosin for BPH. The parameters evaluated were the weighted IPSS score, the IPSS question 8 related to quality of life, the USP score and the Athens Insomnia Scale (AIS) measured at treatment initiation and after 3 months.
  
  
  RESULTS
  Nine hundred and fourteen patients whose average age was 66 years with LUTS for 3.3 years were analyzed. After 3 months of treatment, a significant decrease in IPSS (from 16.2 ± 6.1 to 9.7 ± 5.5, P<0.0001) and USP score (from 10.6 ± 5.1 to 6 0 ± 4.6, P<0.0001) were observed, quality of life (from 67.1% to 14.4% of unsatisfied patients, P<0.0001) and sleep were significantly improved (from 49.2% to 28.9% patients with insomnia, P<0.0001). Among the patients, 21.2% experienced at least one adverse event. The most frequent were abnormal ejaculation (17.2%). And 7.1% discontinued the treatment for this reason. After 3 months of treatment silodosin was continued in 86.9% of patients.
  
  
  CONCLUSIONS
  This large study confirmed the efficacy of silodosin in LUTS associated with BPH with a safety profile that does not affect patient satisfaction.
authors.affiliation: Service d'urologie, CHU, 87042 Limoges, France. Electronic address: aureliendescazeaud@gmail.com.
authors.forename: A
authors.initials: A
authors.lastname: Descazeaud
authors.affiliation: Service d'urologie, clinique Rhône Durance, 84000 Avignon, France.
authors.forename: J-L
authors.initials: JL
authors.lastname: Davin
authors.affiliation: Service d'urologie, CHU Henri-Mondor, 94000 Créteil, France.
authors.forename: A
authors.initials: A
authors.lastname: De La Taille
authors.affiliation: Service d'urologie, hôpital de la Conception, 13015 Marseille, France; Service d'urologie, polyclinique Francheville, 24004 Périgueux, France.
authors.forename: G
authors.initials: G
authors.lastname: Karsenty
authors.affiliation: Service d'urologie, polyclinique Francheville, 24004 Périgueux, France.
authors.forename: G
authors.initials: G
authors.lastname: Kouri
authors.affiliation: Service d'urologie, CHU Cochin, 75014 Paris, France.
authors.forename: M
authors.initials: M
authors.lastname: Zerbib
authors.affiliation: Direction médicale, Bouchara-Recordati, 92800 Puteaux, France.
authors.forename: V
authors.initials: V
authors.lastname: Morris
authors.affiliation: Chaire d'évaluation médicale, CHU de Dijon, 21000 Dijon, France.
authors.forename: F A
authors.initials: FA
authors.lastname: Allaert
authors.affiliation: Service d'urologie, hôpital Dubos, 95300 Cergy Pontoise, France.
authors.forename: P
authors.initials: P
authors.lastname: Coloby
mesh_terms: D058668:Adrenergic alpha-1 Receptor Antagonists / Q000627:therapeutic use*; D000368:Aged; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D059411:Lower Urinary Tract Symptoms / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D017060:Patient Satisfaction; D011446:Prospective Studies; D011470:Prostatic Hyperplasia / Q000150:complications / Q000188:drug therapy*
chemical_list: D058668:Adrenergic alpha-1 Receptor Antagonists; D007211:Indoles; C095285:silodosin
keywords: BPH; HBP; Satisfaction; Silodosin; Silodosine
vernacular_title: Évolution des symptômes du bas appareil urinaire sous silodosine: facteurs influençant la satisfaction des patients.